NEW YORK ( TheStreet) -- Syneron Medical (Nasdaq: ELOS) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Syneron Medical Ltd., together with its subsidiaries, engages in the research, development, marketing, and sale of aesthetic medical products worldwide. Syneron Medical has a market cap of $415.7 million and is part of the health care sector and health services industry. Shares are up 38.4% year to date as of the close of trading on Wednesday. You can view the full Syneron Medical Ratings Report or get investment ideas from our investment research center.
More from Markets
Stocks Finish Down as Wall Street Questions Trade Agreement
Stocks finish down Monday as Chinese officials said they want to talk further about last week's tentative trade agreement between the world's two largest economies.
J&J, Morgan Stanley, Coca-Cola and More - Biggest Earnings for This Week
Here's list of key companies reporting earnings the week of October 14, 2019.
Is a Bear Market Upon Us? Jim Cramer Will Reveal What Investors Needs to Know
What do you do in a bear market? Are we in a bear market? Jim Cramer will be breaking it down in his next members-only Action Alerts PLUS conference call on Wednesday, October 16 at 11:45 a.m. ET.